Introduction
Idiopathic generalized epilepsies (IGEs) belong to a group of epilepsies with no apparent structural brain damage or neurological abnormalities, and they are mainly due to genetic factors. Patients with IGEs are prone to recurrent seizures, which occur both in childhood and in adolescence. Common IGE forms, such as: juvenile myoclonic epilepsy (JME), childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), and epilepsy with generalized tonic-clonic seizures (EGTCS), follow complex inheritance patterns. 1 In most cases identification of genes that underlie predisposition to IGEs is difficult because of clinical and genetic heterogeneity of this group of epilepsies, 2 and only a few susceptibility genes have been identified so far. [2] [3] [4] Among four IGE subtypes, JME appears genetically more distinct, and in many families autosomal dominant inheritance is apparent. 4 This epileptic syndrome is characterized by myoclonic tonic-clonic and absence seizures. It has been found that the risk of developing either JME or related IGEs is higher in relatives of probands with JME, and different subtypes of IGE may coexist within a single family. 2, 5 Chromosomal regions harboring genes encoding the nAChRs were tested for linkage to the juvenile myoclonic epilepsy and strong evidence had been presented that the EJM2 locus, in which the gene encoding the a7 subunit (CHRNA7) is located, contributes to the genetic susceptibility to the JME trait. 6, 7 Mutations of the ion channel genes encoding subunits of nAChR are associated with the familial forms of partial epilepsies classified as autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), but some polymorphisms of the gene coding for the a4 subunit (CHRNA4) also confer genetic susceptibility to the common subtypes of IGE. [8] [9] [10] [11] Suggestive evidence for the Caucasian population came from one of the CHRNA4 polymorphisms, c.594C>T (SNP 1044394), investigated in a group of IGE probands, comprising CAE, JAE and JME patients. 8 Recently, another silent polymorphism within the CHRNA4 (Ser543Ser) have been linked to the group of IGEs in the Taiwanese population. 9 Two other CHRNA4 polymorphisms, 1674 +11 C>T (SNP 45442394) and 1674 +14 A>G (SNP 3827020), located within intron5 of the CHRNA4, are distinguishable by the presence of restriction sites for SsiI or Sty. 12 It has been suggested that the CHRNA4 polymorphisms or putative sequence variants situated near the CHRNA4 locus, confer susceptibility to the common IGE syndromes. In view of a possible association between the CHRNA4 variants and IGEs, we decided to analyze four of these polymorphisms in our sample comprising the JME patients. The a4 subunit gene (CHRNA4) of the neuronal nicotinic acetylcholine receptor (nAChR), linked to an idiopathic partial epilepsy, autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), may also play a key role in the development of the idiopathic generalized epilepsy syndrome (IGE), juvenile myoclonic epilepsy (JME). This study was designed to explore an association of four polymorphisms of the CHRNA4 with JME in Polish children and young patients. The study included 92 JME patients and 222 unrelated healthy individuals. In each group the frequencies of the CHRNA4 c.555C>T, c.594C>T, 1674
+11
C>T, and 1674 +14 A>G polymorphisms were determined using PCR-RFLP analyses. An association between the 1674 +11 C>T polymorphism of the CHRNA4 and JME was evidenced. Allele T (the risk factor) appeared with a significantly higher frequency in the JME patients than in the controls (p = 0.0299). The patients harboring the 1674
CT+TT genotypes showed an increased risk of JME (CT+TT versus CC: OR = 1.925; 95% CI = 1.021-3.629; p = 0.0408). No association was found for the other CHRNA4 polymorphisms tested. The CHRNA4 1674 +11 C>T polymorphism may be a susceptibility factor for epilepsy, and its higher frequency in patients with juvenile myoclonic epilepsy suggests that the CHRNA4 may be one of the candidate genes for this epileptic syndrome. ß 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Methods

Subjects
The subjects of the study were 92 unrelated Polish children and young patients in whom JME was diagnosed, and 222 healthy volunteers. Probands were patients of the Department of Developmental Neurology of University of Medical Sciences in Poznan. All patients were Caucasians aged 6-26 years, and fulfilled diagnostic criteria for JME of the International Classification of Epileptic Syndromes. Healthy individuals, born in Poland, aged 15-35 with no history of any epilepsy syndromes and neurological disorders served as controls. Written consents from all adult patients and parents of the children were obtained, and the local Ethic Review Committee approved the study protocol.
Genotyping
The CHRNA4 genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay, using published PCR primers. 12 The amplification was followed by restriction digestion with the FokI (c.555C>T; SNP 1044393), CfoI (c.594C>T; SNP 1044394), SsiI (1674 +11 C>T; SNP 45442394), and StyI (1674 +14 A>G; SNP 3827020). Digested PCR products were directly analyzed by electrophoresis either on 2% agarose or 10% polyacrylamide gels, and each allele was identified according to its size.
Statistical analysis
The genotype and allele frequencies of the CHRNA4 polymorphisms in the JME patients were compared with the healthy individuals using a case-control study design. Significance was evaluated by Chi-square or Fisher exact test. Odds ratios and 95% confidence intervals were estimated using an online implementation for deviation from Hardy-Weinberg equilibrium and tests for association (http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/ hwa1.pl). In all cases, p < 0.05 was considered as statistically significant.
Results
The data for genotype distribution and allele frequencies of CHRNA4 c.555C>T, c.594C>T, 1674 +11 C>T, and 1674 +14 A>G polymorphisms for the patients and the controls are shown in Table 1 . Distribution of these polymorphisms was consistent with Hardy-Weinberg equilibrium in the patients and in the control group. No significant differences were observed in either the frequency of the CHRNA4 c.555C>T, c.594C>T, and 1674 +14 A>G genotypes or alleles between the patients and the controls. The CC, CT and TT genotype distribution of the CHRNA4 c.555C>T polymorphism was, respectively, 83%, 17%, and 0% for the patients, and 80%, 19%, and 1% for the controls. There were no TT genotypes in the patients. The derived allele frequencies for the C and T alleles were 91% and 9% in the patients, and 90% and 10% in the controls. Studies on the c.594C>T CHRNA4 polymorphism showed similar results (see Table 1 ). The genotype frequencies in the probands were 90% (CC) and 10% (CT), and in the controls: 88% (CC) and 12% (CT). No 594TT homozygotes were identified in each group. The allele frequencies in the patients and the controls were 95% (C) and 5% (T), and 94% (C), and 6% (T), respectively. Analyses of the 1674 +14 A>G polymorphism also revealed that genotype and allelic frequency did not differ between the patients and the control group (see Table 1 ).
On the contrary, the 1674 +11 C>T polymorphism in the patients showed a significant difference when compared to the healthy individuals. The frequency of the T allele of the 1674 +11 C>T polymorphism in the JME group was higher than that in the control group (p = 0.0299). Moreover, no TT genotype was found among the healthy individuals (see Table 1 ). We also undertook the test for association, using the 1674
+11
T as a risk allele (see Table 2 ). The odds ratios (ORs) and the confidence intervals (CIs) were calculated Table 2 The tests for association a of CHRNA4 polymorphisms in JME patients and control subjects. for each genotype and compared with the homozygous one for the genotype of higher frequency among controls, which was set as the reference genotype. When the 1674 +11 CC genotype was used as the reference, the combined 1674
CT+TT genotypes were associated with significantly higher risk of JME (OR = 1.925; CI = 1.021-3.629, p = 0.0408).
Discussion
Genes encoding the nAChR subunits had recently emerged as the candidates for idiopathic epilepsies. Significant evidence for linkage of JME was found to polymorphic loci within the region on chromosome 15q14, in which the CHRNA7 is localized. 6, 7 Two independent investigations, however, have failed to confirm these findings. 13, 14 On the other hand, several mutations of the CHRNA4 gene were associated with ADNFLE. 15 Since the c.851C>T (S284L) mutation of the CHRNA4 was identified in a Caucasian family with ADNFLE, 16 we decided to study the linkage of four CHRNA4
polymorphisms with JME in a sample from the Polish population. Two of these polymorphisms, c.555C>T and c.594C>T, are located in exon5, and two other, 1674 +11 C>T and 1674 +14 A>G, are within intron5 of the CHRNA4. To date, all of these polymorphisms, except the 1674
+11
C>T, had been studied in epilepsy, and in a single report. 8 only one, the c.594C>T polymorphism, was associated with IGE. In this study, the c.594C>T polymorphism had previously been associated with the common subtypes of IGE, but no distinction between JME or absence epilepsies was made. 8 The frequency of the T-allele was higher in the entire group of IGE patients (0.085) compared to the healthy individuals (0.027). However, case-control and family-based study, made by Chioza et al. 10 in 182 Caucasian patients with IGEs (JME, JAE and CAE), as well as in 178 controls, has not implicated the CHRNA4 c.594C>T polymorphism in susceptibility to epilepsy. 10 In this study, the allele frequencies of the 594T polymorphism in IGE probands and controls were virtually the same (0.05 and 0.04, respectively). In our study no significant differences in the T-allele distribution between the patients (0.05) and the control group (0.06) were discerned, and no homozygous 594TT genotype was found in the patients as well as in the control group. Also the c.555C>T polymorphism was not associated with JME, one of the IGE subtypes, similar to that reported for the Kuwaiti Arab children with IGEs (CC = 85%, CT = 14%, TT = 1%). 11 The allele frequencies of the c.555C>T polymorphism in our control group (C = 90%, T = 10%), however, were lower than that reported in other Caucasian populations, where the C allele was found in 70% and the T allele in 30% of cases. 17 The genotype frequencies of yet another polymorphism, 1674 +14 A>G, located 14 bp into intron5, were similar in the IGE patients and controls in the earlier study. 10 In our study, there were also no differences between the genotype frequencies of this polymorphism in the JME patients, and the controls. However, the genotype frequencies in the controls obtained (AA = 38%, AG = 51% and GG = 11%) were different from those originally reported by Chioza et al. 10 (AA = 77%, AG = 18% and GG = 5%). These discrepancies, however, might be due to different populations studied. In our study, another polymorphic variant, 1674 +11 C>T, which was never investigated in epileptic syndromes so far, located 11 bp into intron5 of the CHRNA4 was analyzed. This polymorphism was recently detected in the patients with Alzheimer's disease, but did not have any significant association with AD. 12 On the contrary, the association between CHRNA4 1674 +11 C>T polymorphism and JME was evidenced. We found that the 1674 +11 T allele appeared with a significantly higher frequency in the patients than in the control group and the patients with the 1674
CT+TT genotypes showed increased risk of JME, indicating the 1674 +11 T allele as a risk factor for this form of epilepsy. This demonstrated that the CHRNA4 might be yet another important gene connected with JME. Further investigations are required, however, to substantiate our findings.
